The burden of cancer is increasing in Europe, which accounts for a tenth of the world’s population but a quarter of cancer cases recorded worldwide.
In the EU, without decisive action, lives lost to cancer are set to increase by more than 24% by 2035, according to the European Commission's 'Beating cancer plan'.
To help combat this threat, EMA is exploring how to improve medicine evaluation by using cancer as a pathfinder.
Launched in 2023, Cancer Medicines Pathfinder could have a meaningful impact for patient care and access to innovative therapies.
For more information on cancer medicines and the burden of cancer in Europe, see:
EMA's Cancer Medicines Pathfinder groups its initiatives under three pillars:
The Cancer Medicine Pathfinder builds on the European medicines regulatory network's experience in responding and adapting to the COVID-19 pandemic.
Key to this response was to accelerate development and assessment on COVID-19 medicines.
For more information on EMA's role in tackling COVID-19, see:
EMA's collaboration with the United States (US) Food and Drug Administration (FDA) is an example of both multi-stakeholder dialogue and international collaboration.
EMA exchanges information with FDA and promotes its projects in areas such as oncology education and patient engagement.
For more information, see:
EMA launched a monthly newsletter featuring related news, regulatory actions and activities in oncology.
For more information, see: